CLYM Climb Bio Inc.

🚨 $CLYM (Climb Bio) – Swing Trade Analysis Fundamentals: 6/10 | AI Score: 7.5/10 Trend: Reversing off $8.80 support 📈 Setup: LONG (1–5 Days) Entry: $9.00 – $9.25 Target: $9.85 (TP1) | $10.15 (TP2) Stop-Loss: $8.55 Risk: High (Biotech Catalyst Rebound)

$CLYM Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026 "Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, consistent with Phase 1b data; additional data from the PrisMN Phase 2 study anticipated in 2027"

$CLYM announced early Phase 2 data showing B-cell depletion and PLA2R antibody reduction in pMN patients.

$CLYM 🏥 Climb Bio, Inc. reported initial Phase 2 data showing low-dose budoprutug (200 mg) achieved B-cell depletion, PLA2R antibody reduction, and immunologic remission at 12 weeks in primary membranous nephropathy, with both 200 mg and 600 mg doses generally well tolerated. Market-relevant event

$CLYM released new Phase 1 data showing durable APRIL suppression with 12-week dosing for its CLYM116 candidate.

$CLYM 🏥 Climb Bio, Inc. and Beijing Mabworks Biotech Co., Ltd. presented additional Phase 1 data for CLYM116/MIL116 in healthy volunteers at ASN Kidney Week 2026, showing >90% free APRIL suppression sustained through 12 weeks and ~70% reduction in Gd-IgA1 at 12 weeks. Prioritized by relevance

Climb Bio shares rose 9.15% to $10.62 after Deutsche Bank initiated coverage with a Buy rating and a $28 price target, citing an attractive valuation and an undervalued autoimmune disease pipeline. Analyst David Hoang argued that the stock’s recent decline largely reflected broader biotech-sector weakness rather than company-specific deterioration, creating an appealing risk-reward opportunity. The investment thesis centers on CLYM116, a licensed APRIL inhibitor targeting IgA nephropathy that Deutsche Bank views as a potential best-in-class therapy in a growing market. Additional upside could come from budoprutug, an anti-CD19 therapy targeting B-cell-mediated diseases, including membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. Climb Bio faces several clinical catalysts over the next 12 months, including at least four incremental updates expected in Q4 2026. $CLYM

$CLYM +9.3% intraday (10:37 ET) — Oct 20: Deutsche Bank initiated coverage of Climb Bio with a Buy rating and a 28 USD price target. Daily chart: 10.63 USD after a low of 9.84 USD, back above the 200-day SMA (10.15 USD) and well below the falling 50-day SMA (13.55 USD). The stock has dropped from its August high near 18 USD; the level around 12 USD is the next one visible on the chart. Analysts: Deutsche Bank Buy, 28 USD target (Oct 20); mean target 27.50 USD (Finviz). Not investment advice.